The European Medicines Agency’s (EMA) Committee for Medicinal Products for Human Use (CHMP) announced on 23 July 2020 that it had recommended granting of marketing authorization for the bevacizumab biosimilar Equidacent, which is produced by Centus Biotherapeutics, a joint venture between AstraZeneca and Fujifilm Kyowa Kirin Biologics
- INICIO
-
Genéricos
Novedades
- US generics launch and approval for Dr Reddy’s and Lupin
- Five Chinese companies join UN’s MPP for Covid-19 medicines
- South Korean companies to make generic Bridion and COVID-19 drugs
- Revlimid (lenalidomide) generics launch across Europe
Investigación
- Community pharmacists’ understanding of generic and biosimilar drugs: Lebanon case study
- Reshaping landscape of Japanese generics market – uncertain future of universal health insurance
- Impact of e-bidding procurement on generic omeprazole injection prices in Thailand
- Trajectories of prices in generic drug markets
-
Biosimilares
Novedades
- EMA recommends approval of trastuzumab biosimilar Herwenda
- FDA approves first natalizumab biosimilar Tyruko for MS
- EMA recommends approval of first natalizumab biosimilar Tyruko for MS
- EMA recommends approval of first aflibercept and tocilizumab biosimilars
Investigación
- Barreras de la Enfermedad Inflamatoria Intestinal (EII): un análisis de América Latina
- Biosimilares oftalmológicos en Canadá: la perspectiva de un prescriptor
- Respuesta a Opinión sobre: Cuatro pasos para racionalizar el desarrollo de biosimilares
- Cuatro pasos para racionalizar el desarrollo de biosimilares
- MORE EDITORIAL SECTIONS
- Search
Post your comment